Global Sepsis Diagnostics Market Archives

Development of rapid diagnostic tests/point-of-care techniques, growing cases of sepsis & hospital-acquired infections, and favorable initiatives & funding for sepsis-related research are some of the key factors driving the Global Sepsis Diagnostics Market. However, limited awareness about sepsis is likely to hamper the growth of the Sepsis Diagnostic market. The market is marked by presence of both established players such as bioMérieux, Becton, Dickinson and Company, T2 Biosystems, Thermo Fisher Scientific, Danaher Corporation, Luminex, Bruker Corporation, Abbott Laboratories, Roche Diagnostics, Quidel Corporation and innovative firms such as Seegene Inc., Axis-Shield Diagnostics, Siemens Healthineers, Immunexpress, EKF Diagnostics, Boditech Med, Alifax S.r.l., AdvanDx, Immunexpress and others. Sepsis is a life-threatening medical emergency. It is body's reaction to infection (may be bacterial, viral, fungal, or parasitic) that may lead to a systemic inflammatory reaction, tissue damage, and ultimately organ dysfunction and/or failure. Infections that lead to sepsis frequently start in the lungs, urinary tract, skin, or gastrointestinal tract. Find A Free Sample of Our Research Report : https://meditechinsights.com/global-virtual-clinical-trials-market/request-sample/ As per WHO, globally, sepsis affects around 49 million people each year. Early diagnosis of sepsis is critical for patient outcomes. However, diagnosing sepsis is not an easy task as there is no particular symptom or sign that are directly related to the disease. Evaluation of symptoms (for diseases such as pneumonia and diverticulitis that are caused by gram-negative or positive bacteria, viruses, and fungi can be related to sepsis), evaluation of patient history, physical examination, and laboratory tests (urine test, blood test, and tests related to other medical conditions) are some of the key methods used to diagnose sepsis. Development of Rapid Diagnostic Tests/Point-of-Care Techniques Set to Drive the Sepsis Diagnostics Market Sepsis is a potentially life-threatening condition and early and accurate diagnosis is critical for survival. Currently, clinicians possess limited technology needed to conduct multiplexed and fully quantitative diagnostic tests at the point of care with high sensitivity. Citing the need for rapid diagnostic tests, several research universities and product manufacturers are developing innovative rapid diagnostic tests/point-of-care techniques. For instance, In February 2022, CytoVal, a medical diagnostics company secured additional funding from Biomedical Advanced Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep™ sepsis risk stratification test towards commercial launch Weil Institute members are developing an assay that utilizes nanotechnology to dramatically improve the sensitivity and specificity of a polymerase chain reaction (PCR) detection system to detect bacteria in whole blood without culture. The ability to rapidly detect bacterial DNA will allow physicians to prescribe the “right drug for the right bug” for septic patients Similarly, researchers at the University of Strathclyde have developed an innovative, low cost test for early diagnosis of sepsis. The experimental microelectrode device analyzes patient's blood and provides results in just 2.5 minutes compared to current testing methods for sepsis which takes up to 72 hours. “With sepsis, timing is the key. Advancements in diagnostic speed, range, and accuracy are critical for addressing the continued rise in sepsis cases and deaths. Advent of new rapid diagnostic tests for sepsis can save thousands of lives.” - Senior Director, Leading In-Vitro Diagnostics Manufacturer, United States Favorable Initiatives & Funding for Sepsis Research Sepsis remains a poorly understood condition due to limited diagnostic tools and few specific treatments. In an endeavor to shape the future of sepsis research, The National Institute of General Medical Sciences (NIGMS) has set its priorities to invest in sepsis research in a more targeted and strategic way. NIGMS intends to use the NIH SBIR/STTR program to support preclinical and clinical sepsis studies to develop improved diagnostic tools and therapies. To prevent millions of deaths each year from sepsis, diagnostics companies are also continuously securing funding to develop rapid sepsis diagnostic tests. For instance, In June 2021, HelixBind secured $3 million National Institutes of Health (NIH) grant to support testing of its rapid diagnostic platform for invasive infections associated with sepsis Similarly, in January 2021, Novus Diagnostics secured €2.4 million in funding from European Innovation Council (EIC) Accelerator pilot to commercialize its rapid sepsis test

Tag: Global Sepsis Diagnostics Market

Global Sepsis Diagnostics Market valued at ~$510 million (2021) is poised to observe a high CAGR of 9% in the next 5 years.

Global Biologics CDMO Market is set to soar at substantial CAGR of 14–16% in the next five years.

Oncology Information System Market Projected to Witness High Growth of 8% from 2024 to 2029

The Transplantation Market Expected to Grow at a 9-10% CAGR by 2029, Fueled by Advancements in Transplant Technologies

The Bioburden Testing Market Maintains Strong CAGR with Growing Demand for Sterilization Assurance

The Fluoroscopy Equipment Market is Poised to grow at a CAGR of 5–7%.

The Bionic Contact Lenses Market is poised to grow at a high CAGR of 11-13%

Global Biosimulation Market Envisions a Promising Future to Have a High 15-20% Growth by 2028

Global Intraocular Lens (IOLs) Market Expecting a Decent 5-6% CAGR in the Next 5 Years

The Cardiology Information System (CIS) Market is projected to grow at a healthy CAGR of 8-10% over the next few years.

Global FemTech Market valued at ~$22 billion (2020) is projected to rise at a healthy growth rate of 15% by 2025.